8, 13, 16 A single-dose pharmacokinetic evaluation of alogliptin in patients with moderate hepatic impairment (Child Pugh score of 7 9) showed the maximum concentration (Cmax) and AUC of alogliptin decreased by approximately 10%, while the Tmax increased by 2.5 hours.
Therefore, this study will be performed to evaluate the effects of alogliptin, a DPP-4 inhibitor, on coronary atherosclerosis using FFRCT in patients with type 2 diabetes.
Studies were designed to investigate the chronic metabolic and pancreatic effects of alogliptin (0.03%) plus pioglitazone (0.003%) combination treatment in obese ob/ob mice.
The aims of this study were (1) to examine the renoprotective effects of alogliptin and (2) to establish urinary angiotensinogen (AGT) as a prognostic marker of renoprotective effects of alogliptin in patients with type 2 diabetes (T2D .In 43 patients with T2D (18 women, 66.1 ± 1.71 years), 25 mg/day of alogliptin was added to the traditional hypoglycemic agents and/or nondrug treatments.
When all patients were redivided into two groups, those with higher values of UAGTCR before the treatment (Group H, n = 20) and those with lower values (Group L, Groupp H showed significantly decreased UAlbCR in response to alogliptin (-14.6 ± 8.6 versus +22.8 ± 16.8%, P = 0.033).Urinary AGT could be a prognostic marker of renoprotective effects of alogliptin in patients with T2D.
BACKGROUND: To examine the effects of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the advanced glycation end product (AGE -receptor for AGE -receptoris and albuminuria in Japanese type 2 diabetes patients.
Efficacy of alogliptin, a dipeptidyl peptidase-4 inhibitor, on glucose parameters, the activity of the advanced glycation end product (AGE) - receptor for AGE (RAGE) axis and albuminuria in Japanese type 2 diabetes.
From the subgroup analysis, the effect of alogliptin add-on therapy (alogliptin plus other antidiabetic drug) in lowering HbA1c does not appear superior to alogliptin monotherapy.
These events occurred primarily at the highest dose of alogliptin.
8, 15 In a trial of alogliptin in 54 adult T2DM patients, 25 mg once-daily dosing of alogliptin produced a time following administration to maximum plasma concentration (Tmax) of 1 2 hours, half-life (t1/2) of approximately 21 hours (standard deviation [SD] =8.8), and an approximately linear relationship between dose and area under the curve (AUC) throughout and well beyond the therapeutic range.
